PPARA and diabetes mellitus: The reducing of lipotoxicity and inflammatory mediators in long-term treatment with PPAR-α agonist have shown an improvement in cardiac performances in diabetic patients and a reduction in diabetes-associated cardiovascular risk factors [68].